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Abstract 
The mining industry having been identified as a particularly vulnerable sector to the 
potentially devastating effects of HIV and AIDS, it became clear that proper management 
thereof is essential if we are to mitigate these. Two-hundred-and-seventy-nine of the 720 
patient files from the mine‟s wellness clinic were reviewed for clinical appropriateness. 
These files were scrutinised to evaluate adherence to treatment guidelines. The review was 
conducted using the wellness clinic‟s treatment guidelines, adapted from the South African 
HIV Clinicians Society (SAHIVCS) 2008 guidelines asking the four questions: “when to start 
therapy”, “what therapy to start”, “co-existence of other illnesses”, “when to change therapy”. 
The guidelines were largely adhered to as far as starting the right type of therapy at the right 
time. “When to start therapy” was adhered to in 97.1 percent of the cases, “when to start” in 
99.6 percent. However evaluation of “co-existence of other illnesses” came in at a rather low 
figure of 45.5 percent. Although the need for change of therapy was very low (2.5 percent), 
57.5 percent of those who needed a change in therapy were prolonged on failing regimens for 
periods of more than three months. 
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Opsomming 
Die mynindustrie in Suid-Afrika is as „n uiters kwesbare sektor geïdentifiseer en behoorlike 
bestuur van hierdie sektor is van kritieke belang in die suksesvolle bestuur van MIV/Vigs in 
Suid-Afrika. 
Die mediese inligting van 279 pasiënte is vir die doel van die studie ontleed en die mate 
waartoe pasiënte getrou hou by behandelingsriglyne is in die studie ge-evalueer. Die 
ontleding was gebasseer op die 2008 welwees kliniese riglyne van die South African HIV 
Clinicians Society (SAHIVCS). 
Die studie bevind dat pasiënte in „n groot mate by die kliniese riglyne gehou het en dat die 
datum waarop met behandeling begin is in bykans 97 % van die gevalle ooreenkomstig die 
riglyne was.  
Die grootste bron van kommer was die groot relatief groot aantal gevalle waar die invloed 
van ander siektetoestande nie behoorlik in ag geneem is nie en die MIV/Vigs medikasie nie 
dienooreenkomstig aangepas is nie. 
Voorstelle word in die studie gemaak vir aksies wat geneem behoort te word om „n groter 
mate van voldoening aan die riglyne te bewerkstellig. 
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Chapter 1: Introduction 
The South African economy is expected to be affected by the Human Immunodeficiency 
Virus (HIV) in different sectors and to varying extents. The direct impact of HIV on the size 
of the population (and the size of labour available), the increase in mortality rate and the 
deterioration of the health of the population in general translate into a disruption of the 
economic activities of the country, both at the macro- and micro-economic level. Businesses 
require a stable macro-economy to operate at optimum levels. HIV prevalence figures show 
that the epidemic affects people who are mostly in the prime of their economic life (i.e. 15 to 
49 year olds) (Shisana, Rehle, Simbayi, Zuma, Jooste, Pillay-van-Wyk, Mbele, Van Zyl, 
Parker, Zungu & Pezi 2009:63). The reduction in the productivity by labour is likely to have 
several consequences. Arndt and Lewis (2000:11) found that, in the absence of any 
interventions, the reduction in the real Gross Domestic Product (GDP) growth rate of South 
Africa would be as much as 2.6 percent over a twelve year period as a direct result of AIDS, 
coupled with a reduction in per capita GDP of around eight percent as well as an increase in 
opportunity costs for AIDS-related expenditure.  
Arndt and Lewis (2000) suggest that semi-skilled and unskilled labourers are a high risk 
group and have an infection rate nearly three times that of highly skilled workers. This 
exposes companies with high low-skill level personnel to potential threats to the bottom line. 
Botswana‟s Debswana Diamond Company, which employs just over 6000 employees, found 
a 27.6 percent HIV prevalence rate among its skilled workers. Their prevalence studies 
revealed significant mortality and morbidity with a rise in ill-health retirements from 40 
percent to 75 percent between 1996 and 1999 (Debswana, 2001). 
HIV affects the labour force in different way according to the South African Business 
Coalition on HIV& AIDS (SABCOHA) (2003): 
HIV affects the productivity of the labour force since they have to spend fewer days at work 
due to ill-health. 
The illness and death benefits due to increased morbidity and mortality increase and therefore 
increase the Cost to Company. Lastly, there is also an expected increase in cost to companies 
since more people have to be trained to replace those affected. 
Correct and cost-effective management of HIV in the workplace is vital to the continued 
profitability of any organisation. Clear and precise guidelines should therefore be followed in 
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order to achieve consistency and reduce the cost of running such programmes. A well 
thought-out HIV policy and HIV workplace programme should form the basis of an HIV 
management programme. A HIV management programme that incorporates provision of 
antiretroviral (ARV) drugs is more cost-effective to companies in the long-term. However, 
such provision of drugs should be closely monitored for treatment adherence, proper patient 
follow-up and monitoring as well as correct provision of appropriate drug regimen and 
dosages to avoid drug resistance, side-effects and complications that may arise as a 
consequence. These may prove more expensive than the omission of ARV provision. 
HIV management guidelines assist healthcare workers to follow uniform treatment standards 
and maximise the benefits of HIV treatment. This study set out to ascertain the compliance of 
healthcare workers to prescribed HIV management guidelines in the mining industry. A 
review of literature with regards to the current HIV trends as well as the response by the 
industry is outlined in the first chapter. Research methodologies as well as ethical 
considerations are outlined in Chapter 3, while the results of the research are presented and 
discussed in Chapter 4. Chapter 5 will deal with limitations of the study and 
recommendations going forth. The study summary and conclusion is to be found in Chapter 
6.  
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Chapter 2 : Literature Review 
 
South Africa is now home to about 5.7 million people living with HIV and AIDS (UNAIDS, 
2011). In terms of numbers, this is by far the world‟s highest number of people infected with 
HIV in one country. Sub-Saharan Africa accounts for about 69 percent of the people living 
with HIV globally; with a total prevalence of about 4.9 percent in 2011 (down from 5.9 
percent in 2005 (UNAIDS Global Report, 2012). Although the epidemic seems to be 
stabilising and the number of new infections declining, new infections are still being recorded 
daily nonetheless. UNAIDS (2012) reports a steady, but progressive decline of about 25 
percent of new HIV infections between the years 2001 and 2011 for the sub-Saharan Africa 
region.  
According to UNAIDS (2012) the number of AIDS deaths and morbidity is also on the 
decline which can only augur well for the economy and the population at large. The World 
Health Organisation‟s (WHO) (2011) goal of getting to zero new infections, zero 
discrimination and zero AIDS related deaths appears to be within reach but this is going to 
need a continued commitment from both the public and the private sector. Although these 
figures appear to be impressive and encouraging, the intended target of halving new HIV 
transmission by 2015 as set out in the 2011 United Nations Political Declaration on HIV and 
AIDS is unlikely to be met if efforts are not increased. Continued commitment will need to 
be accelerated by the public and private sectors as well as civil society at large. HIV 
prevalence figures indicate that the worst affected population group is the 15 to 49 year age 
group (Shisana, Rehle, Simbayi, Zuma, Jooste, Pillay-van-Wyk, Mbele, Van Zyl, Parker, 
Zungu & Pezi, 2009; UNAIDS, 2009). This is also the age group in their prime working 
stage.  
 Although the rate of new HIV infections (incidence) seems to be on a steady decline, a 
significant number of people continue to get infected with the virus. An estimated 1.8 percent 
of new infections occurred in 2008 (down from 2.2 percent in 2000), mostly among people in 
their prime working lives (15 to 49 year old) (UNAIDS, 2009). These are people whom the 
South African economy depends on for growth and from whom many families depend for 
their survival. 
The vast majority of HIV infections occur amongst the low-skill employees. The South 
African economy receives a major contribution from the mining sector into the Gross 
Stellenbosch University  http://scholar.sun.ac.za
4 
 
Domestic Product (GDP). According to the South African Chamber of Mines (2012), the 
mining industry contributed about 8.8 percent of the country‟s GDP in 2011 (up from 7.9 in 
2002). The industry also employs about 8.2 of the total private non-agricultural sector 
(Chamber of Mines, 2012). Mining is labour intensive and the mining industry is also a large 
employer of unskilled as well as semi-skilled workers.  The mining industry remains the 
hardest-hit by HIV and AIDS in South Africa (SABCOHA, 2005; Evian, Fox, MacLeod, 
Slotow, & Rosen, 2004). The industry therefore stands to benefit from the protection of these 
workers if it is to continue its economic successes. HIV has the potential to undermine these 
gains if not properly managed. The implementation of HIV management programmes in 
workplaces is therefore crucial in this regard. The very nature of the mining environment 
makes the industry vulnerable to the negative consequences of HIV on a number of levels.  
The high prevalence of single-sex hostels, easy accessibility of alcohol, and high 
concentration of sex workers around mining towns as well as the low education levels of 
most miners makes the spread of HIV easier. 
The economic implications of HIV could prove rather disastrous for businesses if not 
managed properly. SABCOHA (2004) identified mining and manufacturing to be the most 
affected industries. To its credit, the mining industry has been at the forefront of the fight 
against HIV, pioneering the development of workplace HIV policies, programmes as well as 
providing care, treatment and support to employees affected by the epidemic (Ellis, 2007). 
Workplace HIV programmes need to be managed to be both cost-effective and clinically 
appropriate in order to be sustainable in the long term.  
For HIV treatment programmes to be sustainable, they need to be cost-effective, especially in 
resource-limited settings.  
Appropriate patient management is therefore of importance for a number of reasons. Poor 
treatment adherence has the potential to lead to viral mutation and viral resistance rendering 
HIV drugs ineffective (Sethi, Celentano, Gange, Moore & Gallant, 2003). The viral 
resistance testing process is expensive, especially in resource-limited settings. The second 
line-drugs used to treat drug-resistant HIV in resource-limited countries could cost three 
times as much as the amount of first-line medication (Orrell, Harling, Lawn, Kaplan, 
McNally, Bekker & Wood, 2007). Secondly, opportunistic infections are likely to be more 
manifested in the absence of poor viral suppression as a result of decreased antiviral drug 
blood concentration. Not only is the treatment for opportunistic infections expensive, but the 
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rate of hospitalisation tends to increase with an added associated cost. In Cape Town, South 
Africa, in a study evaluating the cost-effectiveness of HAART for 265 HIV-infected adults 
without AIDS (World Health Organization (WHO) stage 1, 2, or 3) and 27 with AIDS (WHO 
stage 4), mean inpatients days per person per year (PPY) for patients with AIDS was 2.04 for 
the HAART versus 15.36 for the No-ART group. The increase in the rate of hospitalisation of 
the patients not on HAART is likely to be a result of opportunistic infections. HAART has 
been instrumental in preventing mortality related to opportunistic infections (Egger, Hirschel, 
Francioli, Sudre, Wirz, Flepp, Rickenbach, Malinverni, Vernazza & Battegay, 1997; Egger, 
May, Chene, Phillips, Ledergerber, Dabis, Costagliola, D„Arminio Monforte, de Wolf, Reiss, 
Lundgren, Justice, Staszewski, Leport, Hogg, Sabin, Gill & Salzberger, 2002; Hogg, Heath, 
Yip, Craib, O„Shaughnessy, Schechter & Montaner, 1998;  Palella Jr, Delaney, Moorman, 
Loveless, Fuhrer, Satten, Aschman & Holmberg, 1998). The added cost of sickness and death 
benefits in poorly managed HIV people as well as the cost of recruiting and training 
replacement employees makes good HIV management good business sense (SABCOHA, 
2004). Lastly, although the cost of HIV drugs has come down significantly over the past 
decade, treatment remains expensive in relative terms in resource-limited settings and use of 
appropriate but lesser expensive drugs and appropriate clinical and laboratory monitoring by 
health professionals is crucial (WHO, 2006). Health workers need to follow prescribed 
treatment guidelines to guard against potential rise in the costs related to poor adherence, 
poor monitoring and poor clinical management of HIV.  
Unless clients/employees present themselves to get tested, they are unlikely to receive the 
proper HIV disease management that they require. The decision by health workers to initiate 
treatment usually depends on either the self-presentation of patients to health facilities to get 
tested or provider-initiated in-house or outreach HIV-testing campaigns .Provider-initiated 
testing and educational campaigns have been shown to be as important, if not more effective, 
as client-initiated health-seeking behaviour in managing HIV. The South African Department 
of Health (DoH) has taken a decision to offer provider-initiated HIV counselling and testing 
(HCT) to every individual presenting themselves for healthcare, replacing the old patient-
initiated voluntary counselling and testing (VCT). The campaign managed to exceed more 
than 73 percent of its intended 15 million people tested for HIV by 2011 (DOH, 2010).  
Uniformity in HIV management is at the heart of success in turning the epidemic around. 
Health workers are more likely to follow treatment guidelines if these are clear, simple and 
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precise. The importance of starting treatment at the right time has been studied and shown in 
a number of studies. Timeous initiation of HAART reduces the morbidity and mortality rates 
and the cost of treatment among HIV infected individuals (Braitstein, Brinkhof , Dabis, 
Schechter, Boulle, Miotti, Wood, Laurent, Sprinz, Seyler, Bangsberg, Balestre, Sterne, May 
& Egger,2006; Lawn , Myer, Orrell, Bekker & Wood, 2005; Merito and Pezzotti, 2006) 
Current studies on what to start and when to start treatment differ by design, size, setting and 
availability, however, the WHO has devised recommendations thereof. Guidelines are 
compiled to guide clinicians when making important decisions about patient management. 
HIV treatment guidelines have changed substantially since they were first published by the 
US Department of Health and Human Services (DHHS) in the late nineties. These guidelines 
have evolved substantially over the past decade and are updated whenever new evidence-
based treatment information comes to light. Initial treatment of HIV positive individuals in 
developed countries recommended ART initiation after adherence counselling when CD4 
count dropped to below 500mmol/l (DHHS, 1998). These have since been amended to 
initiate treatment at a CD4 count of 350mmol/l or less following studies that show no benefit 
for treatment at higher values. In South Africa, current recommendations which take into 
account the lifelong implications of HIV treatment, possible drug toxicities and drug 
resistance recommend ART initiation at a CD4 count of less than 350mmol/l, and the WHO 
clinical staging of HIV infection coupled with existing co-morbidities (The South African 
HIV Clinicians Society, 2008; 2012).  In a review to determine health workers adherence to 
treatment guidelines and treatment of opportunistic infection in adults in the United States, 
Kaplan, Parham, Soto-Torres, van Dyck, Greaves, Rauch, Ellis & Amandus (1999) found an 
encouraging rate of more than 85 percent adherence to prevention of opportunistic infections. 
In Sydney, Australia, Bloch, Hoy, Cunningham, Roth, Bailey, Pierce, Watson & Andrew 
(2012) observed an 87.6 percent adherence on “when to start”, a 69.0 percent adherence on 
“what to start guideline preferred regimens” and a 56.8 percent adherence to co-morbid 
disease assessment. 
In South Africa, Vijayaraghavan, Efrusy, Mazonson, Ebrahim, Sanne & Santas (2007) 
compared the benefits of WHO recommendations versus using the developed countries‟ 
treatment criteria found that the patients on the developed worlds‟ criteria had a higher life 
expectancy and increased cost of treatment coupled with an improved Quality Year Life Year 
(QUALY). However, South Africa, being a developing country with limited resources has 
adopted a treatment regimen which is more in line with that of the WHO (based on the WHO 
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2006 treatment guidelines). The criteria are a far much more advanced stance compared to 
most other developing countries. Although many studies have examined the reasons for non-
adherence to treatment by patients, very little information is available with regards to the 
nature of adherence to recommended treatment guidelines by health workers. What is 
apparent though is that adherence to treatment by HIV positive people is strongly associated 
with patients‟ overall satisfaction and trust with health workers (Ong, De Haes, Hoos & 
Lammes, 1995; Fehr, Nicca, Sendi, Wolf, Wagels, Kiss, Bregenzer, Vernazza, Jäger, Spirig 
& Battegay; WHO, 2006). Adherence to recommended treatment guidelines by health 
workers is likely to strengthen this relationship between health workers and patients with 
favourable outcomes in the fight against the epidemic. Early testing and timeous 
commencement of HIV has been associated with favourable outcomes. Healthworkers‟ 
knowledge of the type of treatment to start as well as evaluation and treatment of other 
illnesses that may impact on HIV treatment failure/success decreases the probability of 
morbidity and mortality. This is likely to be achieved if there are consistencies in treatment 
guidelines followed by healthcare workers.  
The research methodology for this study will be discussed in the next Chapter. 
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Chapter 3: Research Methodology  
  3.1 Research Problem 
Inconsistencies in HIV management can lead to complications in HIV positive employees 
resulting in productivity losses as a consequence of increased employee absenteeism, high 
labour turnover, increased cost of treating AIDS complications and cost of training new 
employees. It is not known if adherence to guidelines in HIV/AIDS management has been 
followed in the management of HIV positive employees. 
  3.2 Research Question 
The research question for this research was: To what extent has the Wellness Clinic adhered 
to prescribed guidelines in employee HIV management for the past three years? 
  3.3 Significance of Study 
Economic growth has been touted by many economic scholars as a “panacea” to many of 
South Africa‟s problems. Most of South Africa‟s social ills have been blamed solely on the 
high poverty levels that are prevalent in the country. Economic success, on the other hand, is 
virtually impossible without the preservation of the available labour base. The preservation of 
the labour force is, therefore, the backbone of South Africa‟s economy. The proposed review 
with focus on the appropriateness of clinical management of HIV in this sector will benefit 
the concerned stakeholders on different levels. 
The mining industry is the single largest private employer in South Africa. The industry is 
also one of the largest employers of unskilled and semi-skilled workers. This is also the 
hardest-hit group in terms of HIV infections. The sector, therefore, stands to be one of the 
biggest beneficiaries of improved health outcomes as a result of good management of the 
HIV epidemic. The South African Business Coalition on HIV& AIDS (SABCOHA) (2003: 
iii) survey found that most businesses surveyed expected HIV to have an impact on their 
businesses in five years‟ time. The increases in labour costs are likely to have a negative 
impact on profitability. The less profitable companies become, the less employment 
opportunities for the community become available, with negative implications for both the 
macro-economy and social development. 
Employees experience both psychological and physical problems as a result of HIV infection. 
Not only does this affect their performance and ability to fulfil their roles as workers, family 
and community members but also impedes socioeconomic development of the country with a 
resultant adverse effect on the macro-economy. In the high-unemployment context such as 
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South Africa, often these employees are the breadwinners. In the event of the breadwinner 
falling ill, the other household members may have to change roles in order to survive. This 
often means that there is an increased burden of looking after the sick family member added 
to the reduction in the family income. The number of female and child-headed households 
tends to increase in this environment with dire consequences for social development, business 
profitability and the economy in general. Proper HIV management is, therefore vital to 
improve socio-economic, macro-economic as well as micro-economic operations in the 
country. 
The health professionals responsible for managing these employees are likely to experience 
less workload and enable them to improve healthcare delivery employee general wellness as 
a result of improved health outcomes and less complications arising from inconsistent HIV 
management. 
  3.4 Aim of the Study 
The aim of the study was to review the HIV treatment programme followed by the 
Zondereinde Wellness Clinic in order to make recommendations to implement prescribed 
best practice HIV management if necessary. 
  3.5 The Objectives of this Study  
The more specific objectives for this study were the following: 
 To identify best practice for HIV management 
 To identify current practice at the wellness clinic 
 To identify the gap between current practice and best practice 
 To make recommendations for the wellness clinic to close the gap between current 
practice and best practice 
  3.6 Research Design and Methods 
 
This is a quantitative content analysis study. The study sought to review the files of those 
who are on the HIV Disease Management programme employed at a mine in Limpopo 
Province, South Africa.   
The study included a review sample of a total of 279 patient records out of a total of about 
720 patient files retrieved from the Zondereinde Wellness Clinic that have been on the 
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Antiretroviral (ARV) programme in the last three years. The study was conducted from 
November 2013 for a period of three months. 
The review included data obtained from the wellness clinic records (whether manual or 
electronic records) as well as pharmacy records. 
The records reviewed included patient history, patient examination, laboratory results, TB 
investigation and treatment as well as assessment of other chronic diseases and pregnancy 
status .Only data reflected explicitly in these records was recorded. If not, these were 
considered not to have been performed. 
A de-identified, web-based data collection form was used to aggregate data including age 
(expressed as a range), sex, laboratory (to be described as ranges rather than absolute values) 
and clinical data (described using the World Health Organisation (WHO) HIV clinical 
staging as opposed to specific illnesses). This will not contain any names. This collection 
form was used to compute data and during analysis. The available HIV ARV management 
data was evaluated for best practice. The mine‟s wellness clinic ART guidelines were used to 
evaluate the data. These were adapted from the South African HIV Clinicians‟ (SAHIVC) 
guidelines released in January 2008. These guidelines were used to look at: 
 When to start therapy (patient and clinical readiness) 
 What therapy to start (the type of regimen to start) 
 When to change therapy and (monitoring of treatment response and toxicities) 
 The evaluation of co-morbidities (other existing illnesses that may impact on 
treatment success/failure and drug interactions) 
Assessment to therapy guidelines 
The assessment to therapy guidelines was clustered into categories as explained above. The 
when to start therapy assessment was determined by: 
When to start therapy 
The following steps had to be fulfilled to satisfy the “when to start therapy” as outlined by the 
guidelines: 
 Pre-counselling about HIV should be given by registered nurse  
 Rapid HIV test to be done after pre-counselling and written consent done  
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 Post counselling should be done by the nurse irrespective of outcome of the test  
 In cases where the rapid test is reactive, blood for Elisa confirmatory test should be  
taken,  
 If the confirmatory test is positive, blood for CD4 only should! be taken & the  
following steps followed:  
 CD4 of less than 350 microliters- counselling for ART by the doctor and wellness 
sister.  
 CD4 of more than 350 microliters and WHO stage 3 or 4 - counselling for ART by 
the doctor and sister  
 WHO Stage 4, irrespective of CD4- counselling for ART by the doctor and  
sister  
 CD4 of more than 350 microliters- counselling by the wellness sister and lifestyle 
modification, 
 FBC,U&E, Viral load, AST, ALT, and CXR are done routinely before initiating ART  
following CD4 review and patient agrees to treatment  
 The following investigations may be done when indicated:  
 Sputum AFB & TB culture when chest x-ray and clinical picture is suggestive  
of TB  
 Lipogram in diabetic and hypertensive patients  
 LFT & hepatitis studies when transaminase is three times higher than the  
upper normal limits  
 Pregnancy tests in all female patients  
 Start two weeks trial of compliance with Vitamin B Complex and Ferrous 
Sulphate (FeS04) immediately after doing  
the routine investigations - (30 days treatment to be issued)  
 Assessment of compliance to be done by nurse after the 2 weeks trial by counting the  
remaining pills  
 Refer to TB & ART policy for starting ART in patients who passed two weeks 
trial of  
compliance  
 Refer patients who failed two weeks trial of compliance to the social worker for re-  
counselling on ART and subsequently to IR if still non-compliant  
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 Patients may only be started on ART after passing the two week trial of compliance  
and have normal routine investigations 
What Treatment to Start 
This was also based on the recommended guidelines of the SAHIVC of 2008. It is based on 
the following: 
Patients who are HIV seropositive and fulfil criteria for ART may be started on first line  
regimen. 
 First line regimen consists of:  
 Two nucleoside reverse transcriptase inhibitors (NRTI‟s) and 
 One non-nucleoside reverse transcriptase inhibitor (NNRTI)  
  Efavirenz or Nevirapine if pregnant for all females of child- bearing potential not 
only pregnant females. 
Evaluation of Co-morbidities 
These refers to the evaluation of any other co-existing illnesses or pre-conditions that may 
impact on the type of treatment selected, the interaction between the treatment of those 
conditions and HAART and the impact of those co-morbidities on the possible progression of 
HIV. 
When to Change Therapy 
Patients on first line regimen developing treatment failure (clinical or virological), drug  
toxicity and drug intolerance may be changed to 2
nd
 line regimen after further evaluation,  
counselling and 6 weeks DOTS on further first line regimen. 
Second line regimen:  
 Didanosine: one tablet, two times a day   
 Abacavir: one1 tablet, two times a day   
 Lopinavir / Ritonavir (Aluvia): two tablets, two times a day. 
Failure to first and second line regimens requiring salvage therapy should be referred to a 
specialist  
 
Stellenbosch University  http://scholar.sun.ac.za
13 
 
3.7 Ethics 
The main ethical consideration in this study was that of confidentiality. The study did not 
conduct any interviews with patients or health workers. The researcher did not intend using 
identifying patient data in accordance with section 16 (2) of the National Health Act (2003), 
therefore individual consent was waived. No other person/people were be allowed access to 
information pertained in the documents under review whilst in the possession of the 
researcher. Each patient record and included in the study was given a pre-coded study 
number. These study numbers, ranging from NPL 001 to NPL 279 were linked to the patients 
file and did not contain identifying data (name, and hospital number). The coded study 
numbers with identifying data will be kept in a password protected digital file to ensure no 
one else has access to them. Ethical clearance was obtained from Stellenbosch University 
before commencing with the study.  
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Chapter 4: Results and Discussion 
 
The data was analysed using the Statistical Package for the Social Sciences (SPSS 16.0). 
4.1 General Information about the Mine 
The mine is a platinum group metals (PGM) producer operating in the western end of the 
bushveld complex in the Limpopo province in South Africa. It‟s a 1989-listed Johannesburg 
Stock Exchange (JSE) company employing over 7000 people. Just over 3500 of these 
employees live on the mine premises in single-sex hostels. 
A comprehensive HIV policy has been drawn up and is visible in the mine premises. As part 
of HIV prevention and general awareness there is an active HIV peer education and health 
awareness drive with intensified wellness campaign days every three months. These 
encompass HIV testing as part of healthy living.  
In terms of management of HIV infection, the company has a dedicated HIV wellness clinic 
focusing exclusively on HIV and AIDS. The company funds the treatment of their employees 
through a health insurance company that they have contracted to manage the processes, 
logistics and clinical outcomes of their members. The said insurance company also staffs the 
clinic with a nurse and a doctor and supports them through their HIV Disease Management 
Programme (HIVDMP). The mine further provides primary healthcare, emergency care as 
well as a dedicated TB clinic in accordance with Department of Mineral Resources (DMR) 
requirements. 
  4.2 Patient Demographics 
Of the 720 patients on HAART at the Wellness clinic 279 were included in the study. These 
consisted of all the patients initiated on HAART for the three year review period undertaken 
between the periods 1 January 2010 and 31 December 2012. Those patients who started 
HAART at other treatment facilities and then transferred to later we not included. Only 
patients started on therapy at the wellness clinic were included in the study. 
  4.3 Results 
The majority of the patients initiated on HAART were male (96.8 percent) (Table 1) and 
those between the ages of 18 and 49 (male and female) accounted for 86 percent of the 
review, while the remainder (14 percent) comprised of the more than 49 years old group 
(Table 4.2). 
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Table 4.1: Gender 
Gender 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid F 9 3.2 3.2 3.2 
M 270 96.8 96.8 100.0 
Total 279 100.0 100.0  
 
 
Table 4.2: Age 
Age 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid <49 240 86.0 86.0 86.0 
>49 39 14.0 14.0 100.0 
Total 279 100.0 100.0  
 
 
When to Start Therapy 
In terms of deciding when to start therapy, the decision to commence therapy was taken 
correctly in 97.1 percent of the cases. 
 
Table 4.3: When to start therapy 
When to Start Therapy 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid No 8 2.9 2.9 2.9 
Yes 271 97.1 97.1 100.0 
Total 279 100.0 100.0  
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
16 
 
What Therapy to Start 
In 99.6 (Table 4.4) percent of the cases the mine‟s wellness clinic staff started the patients on 
the recommended regimens 
 
Table 4.4: What thererapy to start 
What Therapy to Start 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid No 1 .4 .4 .4 
Yes 278 99.6 99.6 100.0 
Total 279 100.0 100.0  
 
Evaluation of Co-morbidities 
 
The evaluation of co-morbidities came at 45.5, lower than the preceding variables. 
 
Table 4.5: Evaluation of Co-morbidities 
Evaluation of Co-morbidities 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid No 152 54.5 54.5 54.5 
Yes 127 45.5 45.5 100.0 
Total 279 100.0 100.0  
 
 
When to Change Therapy 
 
It is encouraging that cases that needed to be changed to second line treatment were only 
seven (2.4 percent), but of those 57 percent were kept on the failing regimen. 
 
Table 4.6: When to change therapy 
When to Change Therapy 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid  272 97.5 97.5 97.5 
No 4 1.4 1.4 98.9 
Yes 3 1.1 1.1 100.0 
Total 279 100.0 100.0  
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  4.4 Discussion 
 Treatment guidelines are formulated to integrate the best possible clinical evidence with the 
best possible cost-effective strategies so as to render patient treatment effective yet 
sustainable. There is a dearth of literature regarding adherence to HIV treatment adherence. 
In the most comprehensive study assessing adherence to treatment guidelines to date, by the 
Australasian Society of HIV Medicine in 2012, adherence to “when to start” was 87.6 
percent, “what to start” was 69.0 percent and “assessment of co-morbidities” was 56.8 
percent 
 
Demographics 
Traditionally females tend to take up HIV counselling and testing more readily than their 
male partners (Venkatesh, Madiba, Bruyn, Lurie, Coates & Gray, 2011). The mining industry 
is largely male-dominated and one would expect to see far less males taking up HIV testing 
than the employees of this mine; but at ten percent of employees on the programme the mine 
compares favourably with the national statistics of eleven percent HIV prevalence nationally 
(Shisana et. al, 2009). However, the mining industry is known to exhibit higher HIV infection 
rates than the general public because of an interplay of related factors. The expressed 
prevalence in the mine is therefore likely to be an under-representation of the true nature of 
the HIV infection rates in the company.  
Of those started on treatment, 86.0 percent were those between the ages of 18 (the legal 
working age in South Africa) and 49. An estimated 17.9 percent of people aged 15 to 49 
years are living with HIV in South Africa (UNAIDS, 2012). This the highest HIV prevalence 
rate amongst different age groups in South Africa (UNAIDS, 2012). This is also the 
economically active section of the population; the fact that they make the largest number of 
employees on treatment serves as comfort as they are likely to restore productivity. 
 
When to Start Therapy 
The mining industry, and more appropriately, this mine under review, is fortunate enough to 
have a comprehensive HIV management programme at the coal face, and the resources to 
make it work. This is reflected in the fact that more than 97.1 percent of patients who needed 
treatment were started on HAART timeously.   Early initiation of HAART prevents 
occurrence of opportunistic infections and rapid deterioration of the immune system. Patients 
started on treatment with very low CD4 counts have been shown to have a slow immune 
recovery process while some never fully recover (Goulet, Fultz, McGinnis & Justice, 2005; 
Justice, 2006). The 97.1 percent adherence to the “when to start therapy” guideline compares 
favourably to the 87.6 percent seen in Australasia in 2012. 
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Figure 4.1: When to Start Therapy 
Those patients who did not fulfil the “when to start‟, eight percent were delayed to be 
initiated even though they met criteria for initiating HAART. They were, however, initiated 
on treatment subsequently. Only one patient was initiated on treatment without any clear 
criteria for doing so. 
Table 4.7: When to start therapy 
When to Start Therapy 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid  270 96.8 96.8 96.8 
Delayed Initiation 8 2.9 2.9 99.6 
No Clear Criteria to Initiate 1 .4 .4 100.0 
Total 279 100.0 100.0  
 
What Therapy to Start 
Guideline-preferred treatment regimen was chosen in 99.6 percent of new patients being 
started on HAART. It is imperative that the correct first-line treatment be adhered to and 
preserved for as long as possible in order to be able to also preserve second-line regimen in 
case of patients failing their current treatment, clinically and virologically.  
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Figure 4.2: What Therapy to Start 
 
Evaluation of Co-Morbidities 
The presence of any other illnesses may be detrimental to the prognosis of the individual if 
not managed properly. In Nigeria, in a retrospective study to evaluate the prevalence of co-
morbidities in HIV infected individuals, 36.9 percent of people on HAART had at least one 
co-morbidity (Denue, Gashau, Ekong & Ngoshe, 2012).  Not only is HIV infection often 
associated with presence of other illnesses as a direct result of the oppressed immune system, 
but the onset of the ageing process and age-related co-morbidities starts earlier than non-HIV 
infected individuals (Appay, Almeida & Sauce, 2007; Bestilny, Gill, Mody & Riabowol, 
2000; Oursler, Sorkin, Smith & Katzel, 2006). Some of these co-morbidities may be a result 
of prolonged lifespan and the normal ageing process since HAART has been shown to 
prolong life by about 20 to 30 years (Hogg, Lima & Sterne, 2008). HAART itself may be 
responsible for the development of these co-morbidities (Bisson, Gross, Miller, 2003; 
Wilson, Chambers, Bacon, Rueda, Ragan & Rourke, 2010). 
It is concerning that there is no record of evaluation of co-morbidities in more than half (54.5 
percent) of those on HAART at the Zondereinde clinic. Untreated and inadequately treated 
illnesses may be detrimental to both company and workers. An increase sick leave taken as 
well as hospitalisation is likely to result as a consequence. This has a potential to result in a 
strain to resources and insurance. Loss of production as well as compromise to the health and 
safety of those employees reporting for work as a result of staff shortages is of concern.  
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Figure 4.3: Evaluation of Comorbidities 
 
Of those patients that were evaluated for co-morbidities, some patients were patients were 
evaluated for other medical, conditions while others were evaluated for TB, but the majority 
had no record of co-morbid evaluation (93.5 percent). 
 
 
 
 
 
Table 4.8 
Evaluation of Cormobidities 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Medical conditions 6 3.9 3.9 3.9 
No TB Screening/Sputum 4 2.6 2.6 6.5 
No TB 
Screening/Sputum/Medical 
conditions 
144 93.5 93.5 100.0 
Total 154 100.0 100.0  
 
When to Change Therapy 
It is encouraging that only seven (2.5 percent) of the 279 patient files under review required a 
change in treatment. This is probably indicative of the early commencement and correct 
choice of treatment for patients. However it should be pointed out, that four out of seven 
(57.1 percent) of patients who needed treatment change were prolonged on ineffective and 
failing treatment regimen.  
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Table 4.9 
Need to Change Therapy 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid No 4 57.1 57.1 57.1 
Yes 3 42.9 42.9 100.0 
Total 7 100.0 100.0  
 
 
 
 
Figure 4.4: When to Change Therapy 
The adherence to guidelines has largely been adhered to with regards to “when to start 
therapy” (97.1 percent”), what therapy to start” (99.6 percent). The low level of co-morbidity 
evaluation (45.5 percent) is concerning considering that per definition AIDS is a syndrome 
consisting of many illnesses. Although only a small number of patients needed to be changed 
to second-line therapy, it is concerning that most of them were unnecessarily prolonged on 
failing treatment for an extended amount of time.  
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Chapter 5: Limitations and Recommendations 
 
  5.1 Limitations 
In an industry that employs well over 500 000 people (Chamber of Mines, 2012), this study is 
but a small one in the bigger employment picture of the mining industry. This study is also 
limited to those who choose to present themselves to the wellness clinic for treatment. There 
may well be a large proportion of the workforce that chooses to receive treatment elsewhere 
in public or private facilities.  
This researcher‟s interpretation of the documents is also limited to that of the attending health 
worker/clinician at the time. This exposes the data collected and the analysed results to bias. 
Another limitation of the study is the fact that only documents in the three year period 
between 2010 and 2013 were analysed. This was a period in which major scale-up of 
antiretroviral treatment was being implemented in South Africa. The workload required of 
the healthworkers at this time may cause some important factors to be overlooked. 
  5.2 Recommendations 
It is recommended that bigger studies with larger reviews and more inclusive documents be 
conducted to determine the actual extent of adherence to guidelines. It is further 
recommended that clear precise guidelines be formulated with regards to assessing patient co-
morbidities in HIV management. It is also apparent that there may not be seamless co-
operation between the wellness clinic, chronic disease department and the TB clinic. It is 
therefore also recommended that guidelines for co-operation and integration amongst the 
three departments. 
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Chapter 6: Conclusion 
 
The South African mining industry is one of the biggest contributors to the GDP. It is also the 
single largest private employer of the South African labour force. In a high unemployment 
rate country as well as high unskilled labour force such as South Africa, the mining industry‟s 
survival is crucial. Because the industry in South Africa is heavily dependent on labour, any 
factors that have the potential to affect the labour force negatively are likely to have a knock-
on effect on production.  Preservation of the labour force is therefore vital.  
The history of mining in South Africa makes those who work in it both vulnerable and 
susceptible to HIV infection. This study sought to establish whether those who are HIV 
positive as a consequence were managed in a consistent and systematic fashion. Part of this 
evaluation was to establish whether in so doing, those responsible for managing these patients 
adhered to prescribed guidelines. The conclusion is that HIV management guidelines were 
largely adhered to. There is one area, albeit an important one, of concern; the management of 
other illnesses tend to be overlooked when healthworkers are focusing on treating HIV and 
AIDS.  
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